Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 1
1986 3
1987 3
1988 6
1989 5
1990 4
1991 1
1992 1
1993 1
1994 5
1995 7
1996 13
1997 10
1998 6
1999 4
2000 5
2001 8
2002 10
2003 13
2004 10
2005 9
2006 13
2007 9
2008 16
2009 12
2010 6
2011 8
2012 14
2013 17
2014 11
2015 16
2016 13
2017 13
2018 16
2019 9
2020 11
2021 11
2022 16
2023 13
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Life and death of circulating cell-free DNA.
Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Kustanovich A, et al. Among authors: peretz t. Cancer Biol Ther. 2019;20(8):1057-1067. doi: 10.1080/15384047.2019.1598759. Epub 2019 Apr 16. Cancer Biol Ther. 2019. PMID: 30990132 Free PMC article. Review.
In Response.
Nisman B, Oleinikov K, Nechushtan H, Maimon O, Atlan K, Peled N, Gross D, Peretz T, Meirovitz A, Grozinsky-Glasberg S. Nisman B, et al. Among authors: peretz t. J Thorac Oncol. 2023 Nov;18(11):e139-e141. doi: 10.1016/j.jtho.2023.08.032. J Thorac Oncol. 2023. PMID: 37879775 No abstract available.
Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics.
Fedyuk V, Erez N, Furth N, Beresh O, Andreishcheva E, Shinde A, Jones D, Zakai BB, Mavor Y, Peretz T, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Maoz M, Zick A, Ron G, Shema E. Fedyuk V, et al. Among authors: peretz t. Nat Biotechnol. 2023 Feb;41(2):212-221. doi: 10.1038/s41587-022-01447-3. Epub 2022 Sep 8. Nat Biotechnol. 2023. PMID: 36076083
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin.
Sadeh R, Sharkia I, Fialkoff G, Rahat A, Gutin J, Chappleboim A, Nitzan M, Fox-Fisher I, Neiman D, Meler G, Kamari Z, Yaish D, Peretz T, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Maoz M, Abu-Gazala S, Ben Ya'acov A, Shteyer E, Safadi R, Kaplan T, Shemer R, Planer D, Galun E, Glaser B, Zick A, Dor Y, Friedman N. Sadeh R, et al. Among authors: peretz t. Nat Biotechnol. 2021 May;39(5):586-598. doi: 10.1038/s41587-020-00775-6. Epub 2021 Jan 11. Nat Biotechnol. 2021. PMID: 33432199 Free PMC article.
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), et al. Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Lancet. 2014. PMID: 24656685 Free PMC article.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
BRCA mutations and reproduction.
Daum H, Peretz T, Laufer N. Daum H, et al. Among authors: peretz t. Fertil Steril. 2018 Jan;109(1):33-38. doi: 10.1016/j.fertnstert.2017.12.004. Fertil Steril. 2018. PMID: 29307397 Free article. Review.
324 results